Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain

Neurocrit Care. 2015 Dec;23(3):386-93. doi: 10.1007/s12028-015-0126-9.

Abstract

Background: Intraventricular hemorrhage (IVH) frequently complicates spontaneous intracerebral or subarachnoid hemorrhage (SAH). Administration of intraventricular tissue plasminogen activator (TPA) accelerates blood clearance, but optimal dosing has not been clarified. Using a standardized TPA dose, we assessed peak cerebrospinal fluid (CSF) TPA concentrations, the rate at which TPA clears, and the relationship between TPA concentration and biological activity.

Methods: Twelve patients with aneurysmal SAH and IVH, treated with endovascular coiling and ventricular drainage, were randomized to receive either 2 mg intraventricular TPA or placebo every 12 h (five doses). CT scans were performed 12, 48, and 72 h after initial administration, and blood was quantified using the SAH Sum and IVH Scores. CSF TPA and fibrin degradation product (D-dimer) concentrations were measured at baseline and 1, 6, and 12 h after the first dose using ELISA assays.

Results: Median CSF TPA concentrations in seven TPA-treated patients were 525 (IQR 352-2129), 323 (233-413), and 47 (29-283) ng/ml, respectively, at 1, 6, and 12 h after drug administration. Peak concentrations varied markedly (401-8398 ng/ml). Two patients still had slightly elevated levels (283-285 ng/ml) when the second dose was due after 12 h. There was no significant correlation between the magnitude of CSF TPA elevation and the rate of blood clearance or degree of D-dimer elevation. D-dimer peaked at 6 h, had declined by 12 h, and correlated strongly with radiographic IVH clearance (r = 0.82, p = 0.02).

Conclusions: The pharmacokinetics of intraventricular TPA administration varies between individual patients. TPA dose does not need to exceed 2 mg. The optimal administration interval is every 8-12 h.

Keywords: D-dimer; Fibrinolysis; Intraventricular hemorrhage; Pharmacokinetics; Subarachnoid hemorrhage; Tissue plasminogen activator.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / etiology
  • Cerebral Ventricles / drug effects
  • Cerebral Ventricles / pathology*
  • Cerebral Ventricles / surgery
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / blood
  • Fibrinolytic Agents / cerebrospinal fluid
  • Fibrinolytic Agents / pharmacokinetics*
  • Humans
  • Injections, Intraventricular
  • Intracranial Aneurysm / complications
  • Male
  • Middle Aged
  • Pilot Projects
  • Subarachnoid Hemorrhage / drug therapy*
  • Subarachnoid Hemorrhage / etiology
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / blood
  • Tissue Plasminogen Activator / cerebrospinal fluid
  • Tissue Plasminogen Activator / pharmacokinetics*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator